Axokine Obesity Trial Setback Weighs Down Regeneron On Wall Street

Regeneron will explore ways to fine-tune its investigational obesity agent Axokine to increase the percentage of patients that do not develop antibodies to the protein, CEO Leonard Schleifer, MD/PhD, said